Novo A/S has purchased Xellia Pharmaceuticals for $700 million.

Oslo, Norway-based Xellia was spun out from Alpharma Inc. in 2008 when it was purchased by London private equity firm 3i Group plc. The target has evolved from a pharmaceutical ingredient maker to a pharmaceutical company that makes anti-infection products.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.